Pharmaceutical - Anti-virals, Diabetes

Filter

Current filters:

Anti-viralsDiabetes

Popular Filters

Six new drugs recommended for approval by EMA’s CHMP

Six new drugs recommended for approval by EMA’s CHMP

27-06-2014

At its end-June meetings, the European Medicines Agency’s Committee for Medicinal Products for Human…

AbasriaAnti-viralsBristol-Myers SquibbCardio-vascularDaklinzaDiabetesEli LillyEuropeFreseniusGE HealthcarePharmaceuticalRegulationTriumeqVelphoroVifor PharmaVizamyl

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

Pharma Summit: Merck’s European president Bruno Strigini highlights importance of innovation

17-03-2014

The president of pharma giant Merck & Co’s (NYSE: MRK) operations in Europe and Canada Bruno Strigini…

Anti-viralsCanadaDiabetesEuropeInterviewsMerck & CoMK-3475OncologyPharmaceuticalRegulationUKVaccines

J&J’s Invokana approved in Europe and Olysio cleared in USA

J&J’s Invokana approved in Europe and Olysio cleared in USA

25-11-2013

It was a good news day for US health care giant Johnson & Johnson, with two of its Janssen subsidiaries…

Anti-viralsDiabetesEuropeInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaOlysioPharmaceuticalRegulation

Bristol-Myers Squibb refocuses R&D strategy

Bristol-Myers Squibb refocuses R&D strategy

08-11-2013

US drug major Bristol-Myers Squibb says it is “evolving its strategic focus in R&D to ensure continued…

Anti-viralsBristol-Myers SquibbDiabetesManagementNeurologicalOncologyPharmaceuticalResearch

Bristol-Myers gets added indication from US FDA for Sustiva; signs second deal with Ambrx

06-05-2013

US pharma major Bristol-Myers Squibb (NYSE: BMY) says that the US Food and Drug Administration has approved…

AmbrxAnti-viralsBiotechnologyBristol-Myers SquibbCardio-vascularDiabetesLicensingNorth AmericaPharmaceuticalRegulationSustiva

Janssen gains FDA approval of Invokana for type 2 diabetes; files simeprevir NDA

02-04-2013

There were a couple of good news items for Johnson & Johnson (NYSE: JNJ) unit Janssen Pharmaceuticals…

Anti-viralsDiabetesInvokanaJanssenJohnson & JohnsonMedivirNorth AmericaPharmaceuticalRegulationsimeprevirTMC435

Regulatory updates on GSK's albiglutide, Roche's hep C test, Activartis AV0113

07-03-2013

UK pharma giant GlaxoSmithKline plc (LSE: GSK) says it has submitted a Marketing Authorization Application…

ActivartisalbiglutideAnti-viralsAV0113BiotechnologyDiabetesEperzanEuropeGlaxoSmithKlineNorth AmericaOncologyPharmaceuticalRegulationRoche

Janssen files for EU approval of canagliflozin in type 2 diabetes; Ferrer pulls Egrifta MAA

27-06-2012

US health care giant Johnson & Johnson's (NYSE: JNJ) European subsidiary Janssen-Cilag International…

Anti-viralscanagliflozinDiabetesEgriftaEuropeFerrer InternacionalJanssenJohnson & JohnsonPharmaceuticalRegulation

Back to top